Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group is rapidly establishing itself as a unique growth story driven by its disruptive Organ Care System (OCS) technology, which addresses the limitations of cold storage and increases the supply of viable organs for transplant. The company's progress in the development and commercialization of OCS Kidney, as well as its plans to use Controlled Hypothermic Organ Preservation System (CHOPS) in its lung and heart transplant trials, positions it as a market leader for years to come. Factors such as new product launches, international growth, and operating margin improvement also contribute to a positive outlook.

Bears say

TransMedics Group is facing challenges with its operating margin and revenue growth, with both metrics declining in the first quarter of 2026. Additionally, management has lowered its price target and expressed concerns about enrollment in its clinical trials. It also faces risks from increasing competition and reimbursement changes. These factors contribute to a negative outlook for TransMedics Group's stock.

TMDX has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 10 analysts, TMDX has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $131.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $131.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.